Classical Hodgkin lymphoma (CHL) affects approximately 8,500 new patients each year, and the initial remission rate is over 80%. Previous studies have shown that brentuximab vedotin (BV) and nivolumab (Nivo) are well-tolerated and effective in treating relapsed or refractory (R/R) CHL, but no real-world data are available for this combination of treatments.
This study, published in the Journal of Clinical Oncology for the 2022 ASCO Annual Meeting, examined the outcomes of a cohort of patients with CHL who received BV+Nivo. The study relied on data from Moffitt Cancer Center between 2018 and 2021, and the cohort included 29 patients. Of these patients, 69% were male. The median follow-up time was 3 months, and the median time from the last treatment with chemotherapy to beginning BV+Nivo treatment was 4.4 months.
Ultimately, it was found that about 50% of the patients received BV+Nivo as second-line therapy, and 66% of these patients underwent autologous hematopoietic stem cell transplant. The median progression-free survival was 21 months, and overall survival was 100%.
In closing, because this is the first real-world study describing the outcomes of BV+Nivo treatment in CHL, further studies are needed to better understand how this approach compares to traditional chemotherapy. However, given the high-risk and refractory nature of the population studied, BV+Nivo showed excellent responses [1].
Source:
[1] Jordan, A., Rose, A., Bangash, A., Isenalumhe, L. L., Gaballa, S., Chavez, J. C., Shah, B. D., Sokol, L., Pinilla-Ibarz, J., Bello, C. M., & Saeed H. (2022, May). A single institution cohort of patients with classical Hodgkin lymphoma treated with brentuximab vedotin plus nivolumab. 2022 ASCO Annual Meeting, Chicago, IL. https://meetings.asco.org/abstracts-presentations/206251
